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of	 America	 (USA)	 approved	 dexmedetomidine,	 the	 most	 selective	
α2-	agonist,	for	use	as	a	constant	rate	infusion	(CRI)	to	provide	seda-
tion	and	analgesia	 in	 intensive	care	units	 (ICU)	during	periods	of	up	







keting	 authorization	 for	 Dexdomitor®	 (Orion	 Corporation,	 Espoo,	
Finland)	 in	 2002	 and	 renewed	 in	 2007.	This	α2-	agonist	 is	 indicated	
for	use	as	a	sedative	and	analgesic	in	dogs	and	cats	to	facilitate	clin-
ical	 examinations,	 clinical	 procedures	 and	minor	 surgeries,	 and	 as	 a	
pre-	anaesthetic	to	general	anaesthesia.	It	is	the	active	enantiomer	of	
medetomidine	(Savola	&	Virtanen,	1991),	which	is	entirely	responsible	
for	 the	 sedative,	 analgesic	 and	 anaesthetic	 sparing	 effects	 (Ansah,	
Raekallio,	&	Vainio,	1998;	Kuusela	et	al.,	2000;	Segal,	Vickery,	Walton,	
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is	only	allowed	if	no	licensed	alternative	is	available,	and	only	to	avoid	
unacceptable	 suffering	of	 the	animal.	 In	addition,	 in	 food-	producing	










A	 literature	 search	 strategy	 included	 the	 search	 engines	 PubMed,	
Google	Scholar	and	Web	of	Science,	and	proceedings	of	the	last	vet-
erinary	 anaesthesiology	 meetings	 (up	 to	 2017).	 The	 keywords	 and	




“total	 intravenous	 anaesthesia,”	 “standing,”	 “pharmacokinetics”	 or	
“pharmacodynamics.”
The	 eligibility	 criteria	 included	 abstracts	 and	 studies	 (published	
or	 online	 articles	 and	 abstracts	 presented	 in	 congresses)	written	 in	
English,	experimental	or	clinical,	blinded	or	nonblinded,	reporting	the	







by	 the	 Oxford	 Centre	 for	 Evidence-	Based	 Medicine	 (Howick	 et	al.,	
2011;	Appendix	1).






design,	 some	 studies	 are	 included	 in	 different	 groups,	 for	 example,	
Duke-	Novakovski,	 Palacios-	Jimenez,	 Wetzel,	 Rymes,	 and	 Sanchez-	
Teran	(2015)	in	both	PIVA	and	TIVA	studies.
4  | REPORTED STUDIES (2005–2017)
4.1 | Studies in standing horses (9)
4.1.1 | Pharmacokinetic (PK) and pharmacodynamic 
studies (PD) (4)
Bettschart-	Wolfensberger	et	al.	 (2005)	 first	 studied	 the	PK	of	an	 i.v.	
3.5	μg/kg	bolus	in	14	ponies,	eight	mature	(4.4	±	1.1	years)	and	six	old	
adults	(20	±	3.2	years),	by	means	of	capillary	gas	chromatography	with	
negative	 ion	 chemical	 ionization	mass	 spectrometry.	 A	 noncompart-
mental	analysis	was	used,	and	PK	parameters	were	the	following:	peak	
concentration	4.60	±	2.86	and	3.77	±	1.52	ng/ml,	half-	life	19.80	±	9.63	
and	 28.96	±	7.61	min	 and	 area	 under	 plasma	 concentration–time	





volume	 (SV)	 and	 cardiac	 index	 (CI)	 decreased	 significantly	 for	 5	 and	









sidered	 a	 noncompartmental	 analysis	 to	describe	 the	PK	of	 a	5	μg/
kg	i.v.	bolus,	by	means	of	liquid	chromatography–mass	spectrometry	
























anaesthesia;	 MACNM,	 minimum	 alveolar	 concentration	 no	 movement;	
TIVA,	total	intravenous	anaesthesia.
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very	laboured	breathing	pattern	that	normalized	by	30	min.	Reduced	
gastrointestinal	motility	occurred	for	60	min	after	drug	administration.	

















by	 approximately	 51%.	The	HHAG	 drug	 concentrations	 required	 to	
obtain	 inhibition	at	half-	maximal	effect	 (IC50)	were	10	 times	greater	





eters	 after	 a	 150	min	 8	μg	kg−1	hr−1	 dexmedetomidine	CRI	 in	 seven	
healthy	horses.	Dexmedetomidine	was	detected	by	LC-	MS,	 and	 the	
parameters	were	 calculated	 using	 noncompartmental	methods.	 The	
harmonic	mean	(SD)	plasma	elimination	half-	life	(Lambda	z	half-	life)	for	












1	mg	kg−1	hr−1	CRI),	 for	 120	min.	 The	 lower	 dexmedetomidine	 infu-
















In	 another	 experimental	 randomized,	 cross-	over	 study	 with	 10	
adults,	 healthy	 horses,	 Risberg,	 Spadavecchia,	 Ranheim,	 Krontveit,	
and	Haga	(2014)	studied	the	sedative	and	antinociceptive	effects	of	




















HHAG	reductions	 for	 the	 treatments	dexmedetomidine	alone	 (54%)	
or	combined	with	butorphanol	 (58%)	occurred	at	15	min	after	bolus	
administration	and	beginning	of	the	CRIs,	with	the	presence	of	ataxia.	
Afterwards,	 HHAG	 reduction	 values	 were	 never	 higher	 than	 50%,	









41%	 and	 48%	 for	 CI	 and	DO2I,	 respectively),	while	 SVRI	 increased	




In	 donkeys,	 the	 sedative	 and	 antinociceptive	 effects	 of	 differ-
ent	 i.v.	boli	 of	α2-	agonists	were	 reported	by	 Lizarraga	 and	Janovyak	
(2013)	 in	 an	 experimental,	 blinded,	 randomized,	 cross-	over	 study	
enrolling	six	adults,	healthy	animals,	using	mechanical	stimuli	for	the	






or	 romifidine.	 Sedation	was	 15–25	min	 longer	 than	 antinociception	
with	all	 treatments.	A	 recent	 study	by	Lizarraga,	Castillo-	Alcala,	 and	
Robinson	 (2017)	 studied	 the	 sedative	 and	 antinociceptive	 (mechan-
ical)	dose-	dependent	properties	of	2,	3,	4	and	5	μg/kg	of	dexmede-





Based	 on	 Bettschart-	Wolfensberger	 et	al.	 (2005),	 Marcilla,	













In	 a	 clinical,	 blinded,	 placebo-	controlled,	 randomized	 study	with	
40	 adults,	 healthy,	 client-	owned	 horses,	 undergoing	 surgical	 proce-
dures	 under	 general	 anaesthesia	 for	 more	 than	 60	min,	 the	 limited	





horses	 showed	 second-	degree	AVBs,	with	 “no	 need	 for	 treatment.”	






In	 another	 clinical,	 blinded,	 randomized	 study	 involving	 20	
adults,	 healthy,	 client-	owned	 horses,	 the	 same	 protocol,	 3.5	μg/
kg	 sedation	dose	 followed	by	a	CRI	 at	1.75	μg	kg−1	hr−1,	 seemed	 to	
be	 more	 adequate	 than	 a	 morphine-	based	 technique	 (0.15	mg/kg	
added	 to	 the	 dexmedetomidine	 sedation	 dose,	 followed	 by	 a	 mor-
phine	 0.1	mg	kg−1	hr−1	 CRI)	 (Gozalo-	Marcilla,	 Steblaj,	 Schauvliege,	



















study	 involving	 six	 adults,	 healthy,	 isoflurane-	anaesthetized	 horses,	
no	 significant	 differences	 in	 cardiopulmonary	 effects	 and	 recov-
ery	qualities	were	detected	between	a	dexmedetomidine	CRI	 alone	
(loading	 dose	 0.25	μg/kg	 followed	 by	 a	 CRI	 of	 1	μg	kg−1	hr−1)	 and	






















An	 experimental,	 blinded,	 randomized,	 cross-	over	 study	 with	
eight	 adults,	 healthy,	 isoflurane-	anaesthetized	 horses	 by	 Risberg,	
Ranheim,	Krontveit,	 Lervik,	 and	Haga	 (2016)	 compared	 a	PIVA	pro-






present	 in	horses	 receiving	a	CRI	of	dexmedetomidine	compared	 to	
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Sacks,	 Ringer,	 Bischofberger,	 Berchtold,	 and	 Bettschart-	
Wolfensberger	 (2017)	 compared	 the	 effects	 of	 medetomidine	 and	












A	 similar	 protocol	 has	 been	 used	 with	 success	 in	 five	 adults,	
client-	owned	 horses	with	 atrial	 fibrillation	 (AF)	 undergoing	 transve-
nous	 electrical	 cardioversion	 (TVEC)	 (Marly-	Voquer,	 Schwarzwald,	
&	 Bettschart-	Wolfensberger,	 2016).	 The	 horses	 were	 sedated	 with	
3.5	μg/kg	 dexmedetomidine,	 in	 two	 parts,	 1.75	μg/kg	 together	





five	horses	 [median	 total	 sedation	dose	 (range)	was	4.5	μg/kg	 (3.5–
10)].	For	maintenance,	only	one	horse	was	maintained	with	a	rate	of	
1.75 μg	kg−1	hr−1	 (median	 total	 infusion	 rate	 [range]	 2.3	μg	kg−1	hr−1 
[1.75–5.3]).	 Good	 recovery	 qualities	were	 observed	 after	 a	 1	μg/kg	
dexmedetomidine	bolus	(one	horse	received	3	μg/kg	as	it	had	exhib-
ited	 difficult	 behaviour	 before	 anaesthesia).	 In	 that	 case	 series,	 the	
authors	suggested	that	dexmedetomidine	may	have	beneficial	effects	
(cardioprotection	and	energy	sparing	effects	on	the	myocardium)	for	





The	 influence	 of	 these	 protocols	 on	 regional	 perfusion	 has	 also	
been	studied.	Neudeck,	Hopster,	and	Kästner	 (2016)	reported	a	de-




tissue	 was	 well	 oxygenated,	 whereas	 microperfusion	 remained	 sig-




cantly	 higher	with	 desflurane,	whereas	 SVR	was	 significantly	 lower.	
The	 LiDCO	 technique	 was	 used	 to	 measure	 CO.	 In	 15	 isoflurane-	
anaesthetized	horses,	the	same	group	of	investigators	studied	the	ef-
fects	of	a	dexmedetomidine	infusion	(3.5	μg/kg	bolus	+	7	μg	kg−1	hr−1)	
on	 the	 peripheral	 gastrointestinal	 α2-	adrenoreceptors	 when	 given	










4.3 | Minimum alveolar concentration no movement 
(MACNM) studies (2)
Two	experimental	MACNM	studies	with	 six	and	 five	ponies,	 respec-
tively,	 have	 been	 published	 using	 dexmedetomidine	CRIs	 using	 the	
same	 methodology.	 The	 sevoflurane	 MACNM	 value	 was	 reported	
to	 be	 2.42%	±	0.55%	 in	 Gozalo-	Marcilla,	 Hopster	 et	al.	 (2013).	 In	
the	 same	 experiment,	 dexmedetomidine	 3.5	μg/kg	 followed	 by	 a	
1.75 μg	kg−1	hr−1	 CRI	 significantly	 reduced	 the	 MACNM	 of	 sevoflu-
rane	 by	 53%	±	15%,	 down	 to	 1.07%	±	0.21%.	After	 an	 i.v.	 bolus	 of	






In	 an	 experimental,	 nonblinded,	 randomized,	 cross-	over	 study,	
Hopster	et	al.	(2014)	reported	a	TIVA	protocol	for	120	min	with	dex-
medetomidine,	comparable	with	a	xylazine-	based	one,	with	mild-	to-	
moderate	 cardiovascular	 depression	 in	 eight	 adults,	 healthy	 horses.	
This	consisted	of	a	3.5	μg/kg	sedation	dose,	followed	by	dexmedeto-
midine	 (7	μg	kg−1	hr−1),	 midazolam	 (0.1	mg	kg−1	hr−1)	 and	 ketamine	








and	 propofol	 (8	mg	kg−1	hr−1)	 CRIs	 after	 sedation	 with	 twice	
0.5	mg/kg	 i.v.	 xylazine	 (first	 dosage	 to	 allow	 thermodilution	
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catheter	 insertion	 for	 CO	measurement)	 and	 induction	with	 ket-
amine	 (2	mg/kg)	 and	 propofol	 (0.4	mg/kg)	 were	 compared	 with	
a	 PIVA	 regime,	 replacing	 the	 propofol	 CRI	 by	 isoflurane	mainte-
nance.	This	TIVA	 protocol	 provided	 adequate	 surgical	 conditions	
in	 six	 adults,	 healthy	 horses	 undergoing	 arthroscopy	 for	 periods	
around	 60–90	min	 in	 an	 experimental,	 nonblinded,	 randomized,	
cross-	over	 study	 (Duke-	Novakovski	 et	al.,	 2015).	 However,	 at	
comparable	 mean	 FiO2	 values	 ranging	 from	 77%	 and	 94%,	 the	









with	 a	 minimum	 infusion	 rate	 (MIR)	 of	 0.04	±	0.01	mg	kg−1	hr−1. 
With	 both	 protocols,	 peripheral	 tissue	 was	 well	 oxygenated,	


















High-	quality	 research	 has	 been	 performed	 in	 the	 last	 decade	 with	
respect	to	the	use	of	dexmedetomidine	in	the	equine.	Based	on	the	
evidence	reported	by	the	studies	reviewed	here,	it	can	be	stated	that	
dexmedetomidine	 is	 an	 attractive	 drug	 to	 be	 used	 in	 horses.	 Its	 ki-
netics	favour	the	use	of	this	drug	for	sedation	in	prolonged	standing	
procedures	and	during	PIVA	and	TIVA.	However,	 in	some	countries	
depending	 on	 national	 legislation,	 scientific	 evidence	 showing	 clear	
advantages	compared	to	licensed	drugs	should	be	provided	to	support	
its	 off-	label	 use	 (e.g.,	 in	EU	 countries).	Unfortunately,	 the	 literature	
comparing	dexmedetomidine	with	other	α2-	agonists	 is	 scarce	and	a	
direct	comparison	between	them	is	difficult.

















following	 an	 i.v.	 bolus	 in	 young	 and	 adult	 ponies	were	 19.8	±	9.63	
and	 28.96	±	7.61	min,	 respectively,	 (Bettschart-	Wolfensberger	 et	al.,	
2005)	 and	 in	 horses	 was	 shorter,	 8.03	±	0.84	min	 (Rezende	 et	al.,	




















171.0)	min	 (Wojtasiak-	Wypart	et	al.,	2012).	 In	a	 three-	compartment	
model,	beta	and	gamma	half-	lives	for	xylazine	were	167.4	±	6.3	and	
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Therefore,	 based	 on	 its	 PK	 profile,	 dexmedetomidine	 may	 be	
useful	 for	 both	 short-	 and	 long-	term	 standing	 procedures.	 Rates	 of	
7 μg	kg−1	hr−1	 after	 a	 bolus	 of	 3.5	μg/kg	 were	 proven	 to	 be	 equi-










anaesthesia,”	 which	 include	 mainly	 three	 requirements:	 (i)	 an	 ade-
quate	 intraoperative	 cardiopulmonary	 function,	 (ii)	 reduction	 in	 the	
inhalant	agent	requirements	and	(iii)	smooth	and	coordinated	recov-
eries	 (Bettschart-	Wolfensberger	 &	 Larenza,	 2007;	 Gozalo-	Marcilla,	
Gasthuys,	&	Schauvliege,	2014,	2015).
First,	 in	 their	 experimental	 study,	Marcilla	 et	al.	 (2010)	 reported	
clinically	 acceptable	 cardiopulmonary	 effects	 observed	 in	 healthy	
ponies	 at	 both	 rates	 studied,	 1	 and	1.75	μg	kg−1	hr−1.	However,	 the	
design	 of	 that	 study	 comprised	 one	 important	 limitation.	 Potential	




ate.	Under	general	 anaesthesia,	 the	 limited	 cardiopulmonary	effects	







in	 regional	blood	 flow,	but	 further	studies	are	needed	to	assess	 the	
clinical	importance	of	these	changes.	It	is	also	very	important	to	note	
that	all	the	studies	involved	healthy	horses.	While	it	may	be	discussed	
whether	 or	 not	 the	 reductions	 in	 cardiopulmonary	 function	 in	 the	









a	 medetomidine	 CRI	 (Bettschart-	Wolfensberger,	 Jäggin-	Schmucker,	
Lendl,	 Bettschart,	 &	 Clarke,	 2001).	 Experimental	 studies	 describing	







tions	 were	 demonstrated	 after	 romifidine	 (Devisscher,	 Schauvliege,	
Dewulf,	&	Gasthuys,	2010),	detomidine	(Schauvliege	et	al.,	2011)	and	
dexmedetomidine	 (Marcilla	 et	al.,	 2012).	The	 same	happened	 in	 the	












Finally,	 as	 the	 third	 requirement	 for	 PIVA	 protocols,	 recovery	
qualities	 after	 dexmedetomidine	 infusions	 are	 from	 good	 to	 excel-
lent,	with	no	apparent	signs	of	excitement	(Benmansour	et	al.,	2014;	
Marly-	Voquer	et	al.,	2016;	Risberg	et	al.,	2016).	After	a	CRI	of	dexme-
detomidine	during	 isoflurane	anaesthesia,	 followed	by	a	 small	bolus	
for	recovery,	the	recoveries	were	better	than	after	infusions	of	saline	
(Marcilla	 et	al.,	 2012),	 medetomidine	 (Sacks	 et	al.,	 2017)	 and	 mor-
phine	(Gozalo-	Marcilla,	Steblaj	et	al.,	2013).	After	a	dexmedetomidine	
infusion,	small	doses	of	 romifidine	have	been	administered	by	other	
authors	 (Benmansour	 &	 Duke-	Novakovski,	 2013;	 Duke-	Novakovski	
et	al.,	 2015),	 probably	 due	 to	 personal	 preferences.	 Small	 doses	 of	
xylazine,	 detomidine	 and	 romifidine	 are	well	 known	 to	 improve	 the	
quality	of	recovery	in	horses	after	inhalant	anaesthesia	(Santos	et	al.,	








thesias	 (Benmansour	&	Duke-	Novakovski,	 2013).	 Its	 use	 in	 the	 last	
case	 is	 justified	by	 the	 favourable	kinetics.	Moreover,	Marly-	Voquer	









mally include an α2-	agonist,	a	centrally	acting	muscle	relaxant	and	an	
i.v.	 anaesthetic	agent,	mostly	ketamine	 (Hopster	et	al.,	2014).	These	
regimes	 produce	 general	 anaesthesia,	 avoid	 the	 cardiopulmonary	
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effects	 of	 inhalant	 anaesthetics	 and	 reduce	 mortality	 but	 must	 be	
limited	 to	 surgical	 procedures	 of	 less	 than	 60–90	min	 (Johnston,	
Eastment,	Wood,	 &	 Taylor,	 2002).	 The	 use	 of	 dexmedetomidine	 is	
attractive	 in	 these	 cases,	 as	 recovery	 times,	 though	 not	 statistically	
different,	were	shorter	compared	to	xylazine-	based	protocols,	mainly	




However,	 the	 use	 of	 dexmedetomidine	 is	mainly	 limited	 due	 to	
current	 legal	 requirements.	Worldwide,	 dexmedetomidine	 is	 not	 li-
censed	for	use	in	food-	producing	animals,	but	only	for	dogs	and	cats.	






A	 common	 complaint	 from	 anaesthetists	 and	 practitioners	 is	
that	dexmedetomidine	does	not	provide	a	 reliable	 level	of	sedation.	
Assuming	 preliminary	 results	 from	 their	 laboratory,	 3.5	μg/kg	 was	




obtain	adequate	 sedation	 levels	 (Marcilla	et	al.,	 2012;	Marly-	Voquer	
et	al.,	2016;	Sacks	et	al.,	2017).
A	 possible	 criticism	 to	 some	 of	 the	 studies	 presented	 in	 this	
review	 is	 that	 the	LiDCO	was	used	 for	CO	measurement	 (Gozalo-
Marcilla,	 Steblaj	 et	 al.,	 2013;	Marcilla	 et	al.,	 2012;	Neudeck	 et	al.,	
2016;	 Risberg	 et	al.,	 2016).	 This	 method	 to	 evaluate	 the	 cardio-
pulmonary	function	 is	nowadays	of	huge	value	 in	research,	mainly	
under	 clinical	 circumstances,	 due	 to	 minimal	 invasiveness.	 The	 in	
vitro	 study	 of	Ambrisko	 et	al.	 (2013)	 confirms	 that	 dexmedetomi-
dine	is	a	drug	that	may	interact	with	the	sensor	but	unlikely	to	cause	














MGM	 involved	 in	 main	 literature	 search	 and	 evaluation	 of	 the	
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A P P E N D I X   1 Levels	of	evidence	are	categorized	and	reported	
adapted	from	Howick	et	al.	(2011)
Level of evidence Description
I Evidence	obtained	from	a	systematic	review	
of	all	relevant	controlled	trials
II Evidence	obtained	from	at	least	one	properly	
designed,	randomized	controlled	trial
III-	1 Evidence	obtained	from	well-	designed,	
pseudorandomized	controlled	trials	
(alternate	allocation	or	some	other	method)
III-	2 Evidence	obtained	from	comparative	studies	
with	concurrent	controls	and	allocation	not	
randomized	(cohort	studies),	case–control	
studies	or	interrupted	time	series	with	a	
control	group
III-	3 Evidence	obtained	from	comparative	studies	
with	historical	controls,	two	or	more	
single-	arm	studies,	or	interrupted	time	
series	without	a	parallel	control	group
IV Evidence	obtained	from	case	series,	either	
post-	test	or	pretest	and	post-	test
V Expert	opinion	without	explicit	critical	
appraisal,	or	based	on	physiology,	bench	
research	or	“first	principles”
12
